ANIKA THERAPEUTICS, INC.

(ANIK)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
22.53 USD   -4.13%
06/10ANIKA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
06/10Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
GL
06/10Anika to Participate in the Sidoti Small Cap Virtual Investor Conference
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization1 740643517328--
Enterprise Value (EV)1 740643423328328328
P/E ratio 27,4x-26,8x128x-29,8x92,6x62,6x
Yield ------
Capitalization / Revenue 6,46x4,93x3,50x2,12x1,93x1,79x
EV / Revenue 6,46x4,93x3,50x2,12x1,93x1,79x
EV / EBITDA 15,0x26,9x31,5x43,8x30,8x16,4x
Price to Book --1,80x---
Nbr of stocks (in thousands) 14 26914 21514 43714 544--
Reference price (USD) 51,945,335,822,522,522,5
Announcement Date 02/20/202003/04/202103/08/2022---
1 USD in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 115130148154170183
EBITDA1 49,223,916,47,4810,720,0
Operating profit (EBIT)1 37,1-28,32,62-13,44,704,74
Operating Margin 32,4%-21,7%1,77%-8,65%2,76%2,60%
Pre-Tax Profit (EBT)1 36,1-28,62,43-13,35,034,98
Net income1 27,2-24,04,13-11,03,555,47
Net margin 23,7%-18,4%2,80%-7,10%2,09%3,00%
EPS2 1,89-1,690,28-0,760,240,36
Dividend per Share ------
Announcement Date 02/20/202003/04/202103/08/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales1 39,535,836,737,939,540,4
EBITDA1 5,75-0,202,610,791,522,57
Operating profit (EBIT)1 1,30-9,12-3,55-3,95-3,16-2,69
Operating Margin 3,29%-25,5%-9,69%-10,4%-7,99%-6,66%
Pre-Tax Profit (EBT)1 1,25-9,17-3,71-3,88-3,08-2,61
Net income1 0,56-5,79-2,93-3,28-2,59-2,16
Net margin 1,41%-16,2%-7,99%-8,67%-6,55%-5,35%
EPS2 0,04-0,40-0,20-0,23-0,18-0,15
Dividend per Share ------
Announcement Date 11/04/202103/08/202205/05/2022---
1 USD in Million
2 USD
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt ------
Net Cash position --94,4---
Leverage (Debt / EBITDA) ---5,74x---
Free Cash Flow1 34,211,43,25-5,9814,98,62
ROE (Net Profit / Equities) 10,7%-8,55%1,48%-2,50%9,40%-
Shareholders' equity1 25528028043937,8-
ROA (Net Profit / Asset) 9,66%-6,89%1,16%-2,10%8,00%-
Assets1 28234835752244,4-
Book Value Per Share --19,9---
Cash Flow per Share ------
Capex1 2,831,635,148,8110,38,50
Capex / Sales 2,47%1,25%3,48%5,71%6,02%4,65%
Announcement Date 02/20/202003/04/202103/08/2022---
1 USD in Million
Previous periodNext period
Estimates
Key data
Capitalization (USD) 327 673 165
Net sales (USD) 147 794 000
Number of employees 297
Sales / Employee (USD) 497 623
Free-Float 98,1%
Free-Float capitalization (USD) 321 395 203
Avg. Exchange 20 sessions (USD) 3 372 673
Average Daily Capital Traded 1,03%
EPS & Dividend
Year-on-year evolution of the PER